Evotec Partners to Identify Therapeutic Targets for Obesity, Metabolic Diseases

Facebook
Pinterest
Twitter
LinkedIn

Here is the SEO optimized article for a biotech publication, using HTML tags for proper formatting on WordPress:

Evotec SE has announced a groundbreaking partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to advance research in the field of obesity and metabolic diseases. This collaboration aims to identify novel therapeutic targets and develop innovative diagnostic and prognostic markers for these prevalent health conditions.

By combining the expertise of Evotec’s drug discovery and development capabilities with Inserm’s cutting-edge research, Lille University Hospital’s clinical insights, and Inserm Transfert’s technology transfer proficiency, the partnership is poised to make significant strides in understanding the underlying mechanisms of obesity and metabolic disorders. The ultimate goal is to translate these findings into effective treatments and improved patient care.